All In Biotech

Drug Trial Radar · NCT06189495

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 30, 2023

Primary completion

Mar 31, 2026

Study completion Oct 31, 2026

Sponsor

Sponsor type
Industry
Collaborators
West China Hospital
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)

Conditions

  • Systemic Sclerosis Associated Interstitial Lung Disease
  • Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)
  • Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Interventions

  • GenSci048Drug

    1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel

  • GenSci048 placeboDrug

    1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first). 4\. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lung function assessment:Subjects' lung function was assessed by FVC .Time frame: FVC will be evaluated simultaneously during the screening period, 4 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, and once every 24 weeks thereafter, From baseline up to 2 years
  2. Lung function assessment:Subjects' lung function was assessed by DLCO.Time frame: DLCO will be evaluated simultaneously during the screening period, 4 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, and once every 24 weeks thereafter, From baseline up to 2 years,early withdrawal/termination of treatment, and when the investigator deems
  3. tLung function assessment:Visual simulation score was used to evaluate Physician's Global Asseessment(PGA)Time frame: "Lung function assessment:The PGA is evaluated during the screening period and once every 12 weeks .From baseline up to 2 years.
  4. Safety evaluation indicator:Adverse EventsTime frame: From baseline up to approximately 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.